Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If one supported Optune, then supports NWBO, you don't turn around and malign either product without compelling new evidence.
Ex- 70 professional co authors have say DCVax-L works. Your a blogger.
I would not accept any settlement even 1.4 billion without a condition that they stop Trading NWBO forever with the exception that they must settle their short position both legal and illegal after the stock price has been adjusted from the settlement.
But what will the Market Cap be at?
The combined net worth of the 7 market makers is what?
They must think they are talking to the SEC for a fine,
At Linda Powers direction NWBO has filed the lawsuit. I as a stock holder agree with filing the suite and you would be hard pressed to find a long stock holder that didn't agree. These 7 Market Makers have both delayed approval and continue to obstruct approval of the only treatment proven to both extend life and offer a cure to about 13% of Both rGBM and nGBM. The facts are Supported by the JA coauthored by 70 doctors. Yet you continue to support the short and or market makers position by your posting. Hopefully, your loved ones are never diagnosed with nGBB. If they are you will be in an ethical dilemma. After approval however, we longs know the choice you will make to save your son's or daughter's life.
Would the Right to import frozen tissue fall under the same license?
Even the normally tight fisted juror would be punitive given the optics. Rich arrogant billionaires against a small company trying to cure cancer.
Scotty if it's illegal, it's illegal. If your going 80 MPH in a 50 and every one is going 80 you can still get a ticket and be fined. So what is your point? it's ok? it is NOT ok.
Murdaugh and Ken Griffin have one thing in common. Both are guilty of Murder but Murdaugh only killed 2 people.
I'm responding to your post not a prior post.
Definitely a BS Hit peace unless you totally don't believe the 70 doctors that coauthored the Journal Article.
Sounds like the completion date of most construction projects after Covid-19. This said, I will hold until the 1 year warranty expires.
Exactly what LP said they were going to do.
Nice Post!
Great Post!
I would prefer a partnership with Merck not a buyout.
Has anyone done any research into our 7 friends?
On December 1, 2022, we filed a Complaint in the United States District Court for the Southern District of New York against certain market makers:
1 Canaccord Genuity LLC,
Washington D.C., Aug. 14, 2019 —
The Securities and Exchange Commission today charged Canaccord Genuity LLC, a broker-dealer headquartered in New York City, with enabling trading in dozens of thinly-traded securities without conducting the review required by the federal securities laws.
2 Citadel Securities LLC, Dec 14, 2022 · Holy shit, $65-billion in securities that Citadel has sold and not bought yet. Yoooo! Hedgies r fuk, hype-hype-hype! And here’s why. As previously mentioned, the liabilities in Citadel’s filing covered the entire operating period of 2021. A year in which the global stock market fuckin’ ripped, with an overall gain in the S&P of 27%.
3 G1 Execution Services LLC, The Financial Industry Regulatory Authority recently took disciplinary action against G1 Execution Services, LLC, a Chicago brokerage firm, for alleged deficiencies in the process of executing customer orders.
The findings pertained to orders from the firm’s clients on behalf of their customers for over-the counter securities. In its Letter of Acceptance, Waiver and Consent (AWC), FINRA stated that G1 Execution did not provide the best execution of these orders “by failing to use reasonable diligence to ascertain the best market for the subject securities and by failing to buy or sell in such a market so that the resultant prices to the customers were as favorable as possible under prevailing market conditions.”
FINRA stated that the manual process used by GI Execution Services for comparing customer orders resulted in the firm at times missing better priced messages and not executing orders at the best available price. Another finding concluded that the firm did not make reasonable efforts to execute against the market makers quotation within 30 seconds following receipt of a customer’s order, resulting in orders not being handled properly.
In addition, the authority found there were shortcomings in the firm’s supervisory system. According to FINRA, the system did not account for price opportunities available through its electronic messaging service. With reviews of those prices excluded, “it had no way to determine if its customer orders received an inferior execution to one available via the messages.”
Under the terms of the AWC, G1 Execution Services was censured and fined $575,000. It was also ordered to pay $816,618.75, plus interest, in restitution to its customers. The company did not admit or deny the charges, but consented to the sanctions and the entry of FINRA’s findings.
4 GTS Securities LLC, No. 16-cv-04291 (E.D. Pa. filed Aug. 8, 2016) On July 22, 2019, the Securities and Exchange Commission obtained final judgments against three former senior executives of the now-defunct brokerage consulting business, Global Transition Solutions, LLC (GTS), for their roles in a multimillion dollar transition management fraud.
5 Instinet LLC, Lime Trading Corp. a Nomura company
Nomura to Pay Misled Bond Customers $25 Million to Settle SEC Charges
FOR IMMEDIATE RELEASE
2019-131
Washington D.C., July 15, 2019 —
The Securities and Exchange Commission today instituted two related enforcement actions against Nomura Securities International Inc., which has agreed to repay approximately $25 million to customers for its failure to adequately supervise traders in mortgage-backed securities.
The SEC orders find that Nomura bond traders made false and misleading statements to customers while negotiating sales of commercial and residential mortgage-backed securities (CMBS and RMBS). According to the SEC’s orders, several Nomura traders misled customers about the prices at which Nomura had bought securities, the amount of profit Nomura would receive on the customers’ potential trades, and who currently owned the securities, with traders often pretending that they were still negotiating with a third-party seller when Nomura had, in fact, already bought a security. The SEC’s orders further find that Nomura lacked compliance and surveillance procedures that were reasonably designed to prevent and detect this misconduct, which inflated the firm’s profits on CMBS and RMBS transactions at its customers’ expense. The SEC previously filed charges against two CMBS and three RMBS traders at Nomura, whose misrepresentations are described in the SEC’s orders.
“Firms acting as dealers in opaque markets like those for CMBS and RMBS must take steps to prevent misleading communications with their customers,” said Daniel Michael, Chief of the SEC Enforcement Division’s Complex Financial Instruments Unit.
“These orders underscore that firms must have adequate supervisory procedures, particularly surrounding the sale of complex instruments,” said Sanjay Wadhwa, Senior Associate Director of the SEC’s New York Regional Office. “Weak procedures, such as those found here, may enable employee misconduct to go undetected.”
To settle the charges that it failed to reasonably supervise its traders, Nomura agreed in the two orders to be censured and to reimburse customers the full amount of firm profits earned on any RMBS or CMBS trades in which a misrepresentation was identified, paying over $20.7 million to RMBS customers and over $4.2 million to CMBS customers. Nomura also agreed to pay a $1 million penalty in the RMBS-related case and a $500,000 penalty in the CMBS-related case. Both orders note that the penalty amounts reflect substantial cooperation by Nomura during the SEC’s investigation, including remedial efforts by the firm to improve its surveillance procedures and other internal controls.
The SEC’s CMBS investigation and ensuing litigation was conducted by staff in the New York Regional Office, including Ladan Stewart, Chevon Walker, Richard Hong, and George Stepaniuk. The case is being supervised by Mr. Wadhwa. The RMBS investigation and ensuing litigation was conducted by staff in the Complex Financial Instruments Unit and the Boston Regional Office, including Susan Curtin, Kerry Dakin, Rua Kelly, Al Day and Celia Moore. The case is being supervised by Mr. Michael.
6 Susquehanna International Group LLP, Susquehanna International Group Engineer For Theft Of Trading Code
Nathan Vardi
Former Staff
Following the money trail
Apr 13, 2017,09:06pm EDT
A high-frequency trading software developer was charged on Thursday by Joon Kim, the acting U.S. Attorney in Manhattan, with attempting to steal quantitative trading code from a secretive financial firm based in the Philadelphia area that specializes in making markets for options.
Dmitry Sazonov, 44, who worked for Susquehanna International Group for 13 years as a software engineer, was arrested in the lobby of Susquehanna’s New York offices on Wednesday by agents of the Federal Bureau of Investigation.
According to the criminal complaint, Sazonov tried to steal source code linked to an updated trading platform Susquehanna has been developing for years to generate exchange and market orders. Sazonov started his effort to steal the proprietary trading code in February, the complaint says, after learning his supervisor had resigned.
Federal prosecutors claim that Sazonov, fearing he would be fired, downloaded the source code to his company computer and deployed a computer program that may have used steganography to break up data and hide data within other files, including personal tax and immigration documents. Sazonov attached zip files containing the quant trading code to two saved emails addressed to a personal account, but he was fired and immediately escorted out of Susquehanna’s New York offices in February before he had a chance to send the emails, the complaint says.
PROMOTED
The feds say Sazonov kept asking to get his personal computer files back from his corporate computer and showed up on Wednesday afternoon in the lobby of Susquehanna’s New York offices thinking he was going to have them returned. There, an FBI agent pretending to be a Susquehanna employee handed Sazonov a disk and he was arrested, federal prosecutors say.
Federal prosecutors and Susquehanna did not respond to calls and emails requesting comment on Thursday evening. Sazonov’s LinkedIn page shows he was educated in Russia and has been working at Susquehanna since 2004, developing “strong experience with trading application development.” The complaint filed by federal prosecutors says Sazonov has worked at the firm that fired him since 2004 and that the firm is headquartered in Pennsylvania with offices in New York. The feds also say the trading platform Sazonov worked on trades $300 million in options daily. Susquehanna is known on Wall Street for its options trading.
Last week federal prosecutors in Manhattan also charged Jim Zhang with stealing computer code related to algorithmic trading models at an unnamed New York-based financial firm.
Federal and state prosecutors in New York have shown an intense interest in going criminally after employees of quantitative trading firms who they believe have stolen trading code. But in recent years Manhattan District Attorney Cyrus Vance has taken the lead in the area after the controversial saga of Sergey Aleynikov. The former Goldman Sachs quantitative trading researcher was initially prosecuted by federal prosecutors starting in 2009 for allegedly stealing secrets. He was convicted by a federal jury but a federal appeals court overturned the decision. Aleynikov was later prosecuted again by District Attorney Vance, found guilty by a jury, acquitted by a judge, and then essentially found guilty again by an appeals court earlier this year.
7 Virtu Americas LLC SEC Orders Virtu to Pay $1.5 Million Penalty for Violations of Regulation SCI
ADMINISTRATIVE PROCEEDING
File No. 3-18563
September 30, 2019 - The Securities and Exchange Commission today announced that Virtu Americas LLC (f/k/a KCG Americas LLC) agreed to pay $1.5 million to settle charges for failing to comply with Regulation SCI. The Commission adopted Regulation SCI to strengthen the technology infrastructure and integrity of the U.S. securities markets.
According to the SEC's order, KCG Americas operated an alternative trading system, or ATS, commonly referred to as a "dark pool." An ATS that exceeds certain trading volume thresholds is required to comply with Regulation SCI. The SEC order finds that KCG Americas implemented an automated system that was intended to keep its dark pool's trading volume below the volume thresholds by discontinuing trading in particular securities before the thresholds were met. KCG Americas relied on this system for more than a year and half. However, according to the SEC's order, the system did not function as intended, causing trading to exceed the thresholds that triggered the need to comply with Regulation SCI. Despite being subject to Regulation SCI, the firm failed to comply with various provisions of Regulation SCI from November 2015 through April 2017. Specifically, the SEC's order finds that KCG America did not: (a) establish the policies and procedures required by Regulation SCI; (b) file any quarterly or annual reports required by Regulation SCI; (c) conduct an annual Regulation SCI compliance review; (d) comply with various business continuity and disaster recovery plan requirements of Regulation SCI; or (e) maintain the books and records required by Regulation SCI.
The SEC's order finds that Virtu willfully violated the policy and procedure, reporting and recordkeeping provisions of Rules 1001, 1003, 1004, and 1005 of Regulation SCI, promulgated under the Securities Exchange Act of 1934. Without admitting or denying the SEC's findings, Virtu consented to the entry of a cease and desist order and agreed to be censured and to pay a penalty $1.5 million.
The SEC's investigation was conducted by Andrew R. McFall of the Cyber Unit and the Chicago Regional Office and Mandy Sturmfelz of the Market Abuse Unit. The investigation was supervised by Joseph G. Sansone, Chief of the Market Abuse Unit, Kathryn A. Pyszka, Associate Director of the Chicago Regional Office, and Amy Flaherty Hartman, Assistant Regional Director of the Chicago Regional Office. The Office of Compliance Inspections and Examinations Technology Controls Program conducted the examination that led to the investigation. The examination team included Lisa Robinson, Scott Aryan, Ann Moles and Rich Hannibal.
Merck will burn the market makers as soon as they believe they could loose billions in potential revenue when they believe NWBO will survive without them and she will turn to their competitors. As Check Point Inhibitors are a dime a dozen but there is only one DCVax-L. Feel Free Linda to cut Bait.
I have done my due diligence and years ago invested in NWBO because I believed DCVax-L worked. It turns out, I was right. Even though the Market Makers still make this a risky investment, I believe Linda Powers is more astute than the 8 market makers put together and I believe she will prevail. As far as the DD, I believe he is a great asset and communicator that does damage to the shorts and that's why your bitching. Good Luck, your going to loose the long game.
So your saying, despite the outstanding Phase 1/2 results with Keytruda, Merck will refuse to partner with with NWBO despite a patent extension and BILLIONS in revenue. To that I say Money talks and the bullshit shorts will walk.
Really, in Hoffmann & DD I trust. You smell fishy.
If I was LP I would want to meet with KG. Not only would I want $ a demand would be that he STOP PLAYING GAMES!
No way Ex plenty of shares and not that long until approval.
That's why we are in court with the Market Makers.
I didn't know you depended on LP for your knowledge of UK regulations. If I was in her shoes, I would not be transparent at all. The manipulation that took place on 5/10/22 dictate her management philosophy and transparency. All good managers adapt or die like the dinosaurs.
They are 2 process that can run concurrently but the MIA approval must complete first or at the same time.
Hygro- As stated previously on this board, Matthias Preusser and Martin J. van den Bent have had or have a relationship with Novacure. These venal individuals are not trying to advance science only stifle it for a few coins of gold.
Novacure = No Cure. it is only false hope.
HYGRO -I asked you for names not rhetoric.
Let's see the success rate and then talk.
Bull S. the SP started falling PRIOR to the meeting. The presentation was excellent.
I would be shocked if new trials were not being planned with the survival rates we are hearing with he combination trial with Keytruda. Linda is not one to put all of her eggs in one basket.
Absolutely we want more of LP. She is wonderful and will see DCVax-L through until it is approved by all 4 RA's.
Who is "We"?
Optune is like a leech on a dead dog. Its days are limited.
They must be pretty good at scamming if they convinced the 70 doctors that peer reviewed the data for the JA that the trial was a successful. Sounds like you the scammer.
If it were not for 8 Market Makers DCVax-L would currently be the SOC NOW. Instead we play cloak and dagger games with these idiots while both children and adults die. News - DCVax will be approved. The short squeeze is inevitable. Give it up and save some lives.
Excellent Post DD.
Optune gives people false hope and I don't know if that is better or worse than no hope. DCVax-L has a fat tail which will give them real hope.